Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease

Recent epidemiological evidence suggests that some antihypertensive medications may reduce the risk for Alzheimer disease (AD). We screened 55 clinically prescribed antihypertensive medications for AD-modifying activity using primary cortico-hippocampal neuron cultures generated from the Tg2576 AD mouse model. These agents represent all drug classes used for hypertension pharmacotherapy. We identified 7 candidate antihypertensive agents that significantly reduced AD-type β-amyloid protein (Aβ) accumulation. Through in vitro studies, we found that only 1 of the candidate drugs, valsartan, was capable of attenuating oligomerization of Aβ peptides into high-molecular-weight (HMW) oligomeric peptides, known to be involved in cognitive deterioration. We found that preventive treatment of Tg2576 mice with valsartan significantly reduced AD-type neuropathology and the content of soluble HMW extracellular oligomeric Aβ peptides in the brain. Most importantly, valsartan administration also attenuated the development of Aβ-mediated cognitive deterioration, even when delivered at a dose about 2-fold lower than that used for hypertension treatment in humans. These preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity and may protect against progressive Aβ-related memory deficits in subjects with AD or in those at high risk of developing AD.

Recent evidence suggests that the use of certain antihypertensive drugs may decrease the incidence of AD (1–4). For example, based on their analysis of the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register (containing reports of trials from all major medical databases), Lopez-Arrieta and Birks (1) reported that the dihydropyridine Ca²⁺ channel receptor antagonist nimodipine decreases the incidence of AD in subjects with hypertension. Additionally, the double-blind placebo-controlled Systolic Hypertension in Europe Trial reported that long-term antihypertensive therapy with nitrendipine, another Ca²⁺ channel receptor blocker, reduced the risk of dementia, primarily AD-type, in hypertensive cases after a median follow-up of 2 years (4), while Guo et al. (3) reported that the combination of certain β-adrenergic blockers and dihydropyridine Ca²⁺ channel receptor antagonists protected elderly hypertensive subjects from developing AD. Last, the Cache County Study of Memory and Aging concluded that the use of antihypertensive medications is associated with a reduced incidence of AD among subjects 65 years of age and older, with the greatest reduction seen in the use of K⁺-sparing diuretics (2).

Despite this encouraging evidence, other studies have failed to support the efficacy of antihypertensive agents in AD dementia. In particular, the Rotterdam study reported that the use of antihypertensive drugs did not significantly affect the relative risk for developing AD among 7,046 elderly subjects who were free of dementia at baseline (5). Moreover, several randomized trials for the prevention of cardiovascular disease (e.g., Systolic Hypertension in the Elderly Program [SHEP; ref. 6], the Medical Research Council [MRC] trial [ref. 7], and the Study on Cognition and Prognosis in the Elderly [SCOPE; ref. 8]) concluded that the use of certain β-adrenergic blockers, thiazide diuretics, or angiotensin II type 1 receptor blockers (ARBs; e.g., candesartan), respectively, did not improve cognitive performance. Thus, at present there is inconsistent evidence regarding the influence of antihypertensive drugs on AD incidence and/or pathogenesis.

In an effort to clarify this discrepancy, we carried out a high-throughput drug screening to test the hypothesis that antihypertensive drugs might influence AD through mechanisms affecting β-amyloid protein (Aβ) neuropathology, independent of blood pressure–lowering activity. Abnormal accumulations of Aβ peptides in the brain are associated with a cascade of cellular events resulting in cognitive decline (9). Aβ species with different amino and carboxyl termini are generated from the ubiquitously expressed amyloid precursor protein (APP) through sequential proteolysis by β- and γ-secretases (10–12). A third proteolytic enzyme, α-secretase, may reduce Aβ generation by cleavage of APP within the Aβ peptide sequence (13). While aggregation and precipitation of Aβ peptides into extracellular amyloid plaque deposits in the brain are key pathological features of AD, recent studies indicate that accumulations of soluble high-molecular-weight (HMW) extracellular oligomeric Aβ species, rather than deposition of amyloid per se, might be specifically related to spatial memory reference deficits (14–19).

We report that certain antihypertensive drugs are able to lower Aβ in vitro. We also found that the ARB valsartan is able to lower Aβ and inhibit Aβ oligomerization into soluble HMW extracellular species in vivo. These effects were seen even at a dose equivalent to approximately 2-fold lower than that commonly prescribed for the treatment of hypertension in humans. The functional relevance of this finding was confirmed by evidence that valsartan’s Aβ-lowering activity in the brain coincided with attenuation of spatial memory reference deficits in Tg2576 mice, in the absence of detectable blood pressure–lowering activity.

Identification of antihypertensive drugs with AD-modifying properties. Our high-throughput screening study assessed 55 antihypertensive drugs representing all pharmacological classes of currently available antihypertensives (see Complete list of 55 commonly prescribed antihypertensive drugs). We found that 7 of the 55 agents significantly reduced the accumulation of Aβ_1–40 and Aβ_1–42 in primary embryonic cortico-hippocampal neuron cultures derived from the Tg2576 mouse AD model (20). Aβ reductions were observed in a dose-dependent fashion (Table 1). The predicted drug concentrations resulting in a 50% inhibition of steady-state Aβ peptide levels (EC₅₀) in the conditioned medium were calculated at a micromolar range (Table 1). No neurotoxicity was detected with any of the 7 agents, as assessed by lactate dehydrogenase (LDH) activity at drug concentrations up to 10 μM (Table 1).

Table 1

Identification of 7 antihypertensive drugs with Aβ-lowering activity in vitro

The 7 Aβ-lowering antihypertensive agents found to be effective in attenuating the accumulation of Aβ_1–40 and Aβ_1–42 are not specific to any single pharmacological class or clinical indication (see Complete list of 55 commonly prescribed antihypertensive drugs). The drugs belong to 6 different pharmacological subclasses, all of which are prescribed for the treatment of hypertension: (a) propranolol HCl, a β-adrenergic blocker; (b) carvedilol, an α/β-adrenergic blocker; (c) valsartan and losartan, ARBs; (d) nicardipine HCl, a Ca²⁺ channel blocker; (e) amiloride HCl, a K⁺-sparing diuretic; and (e) hydralazine HCl, a vasodilator (see Complete list of 55 commonly prescribed antihypertensive drugs).

Recent evidence indicates that spatial memory reference deficits in Tg2576 mice are primarily influenced by the accumulation of soluble, extracellular HMW Aβ species, rather than the deposition of total guanidine-extractable Aβ peptides in the AD-type amyloid plaques in the brain (15). Based on this evidence, we investigated the role of the 7 identified antihypertensive drugs in preventing Aβ oligomerization into soluble HMW species in vitro.

Using an established in vitro oligomerization assay (21), we found that among the 7 drugs identified, valsartan (100 μM) significantly reduced the accumulation of HMW Aβ peptide species, while losartan was effective to a lesser extent. In contrast, propranolol HCl, carvedilol, nicardipine HCl, amiloride HCl, and hydralazine HCl had no effect on Aβ oligomerization (Figure 1A). Quantitative analysis showed that valsartan (10 μM) significantly prevented, by greater than 5-fold, the oligomerization of Aβ_1–42 (and Aβ_1–40; data not shown) into a HMW (>40 kDa) Aβ peptide species relative to vehicle-treated control peptides, as assessed by Western blot assay in vitro (Figure 1B). Consistent with this evidence, using a dot blot immunoassay with an antibody (A11) that selectively detects HMW Aβ species with molecular masses greater than 40 kDa (22), we found that valsartan prevented Aβ_1–42 oligomerization in vitro, relative to vehicle-treated peptides (Figure 1C), 24 hours after incubation.

Figure 1

Valsartan prevents oligomerization of Aβ_1–42 peptide into a HMW Aβ species in vitro. (A) Western blot analysis of Aβ_1–42 oligomers in the presence of losartan, valsartan, carvedilol, hydralazine, propranolol, nicardipine, or amiloride. Bands at 3.5 kDa represent the monomeric Aβ form, whereas the smear between 55 and 130 kDa represents the oligomeric form of Aβ. (B) Valsartan decreases the accumulation of HMW Aβ_1–42 species. Inset: Nonaggregated Aβ_1–42 control (lane 1). Representative Western immunoblot of Aβ_1–42 in the absence (lane 2) or presence of 10 μM valsartan (lane 3). (C) Quantitative dot blot analysis of valsartan inhibition of Aβ_1–42 oligomerization. The same samples used in B were subjected to dot blot analysis using oligomer-specific antibody A11. Inset: Representative dot blot image. Results are expressed as percent of negative control (negative control presents nonaggregated Aβ), and values represent mean ± SEM. *P < 0.05.

Compared with other antihypertensive compounds that we found to lower Aβ, valsartan had stronger in vitro anti-Aβ oligomerization activity. Because of this consideration and the good tolerability and safety record of valsartan in the treatment of hypertension (23), we proceeded with a series of in vivo studies to assess any functional beneficial role of the agent in preventing AD-type spatial memory reference deficits and Aβ neuropathology in adult Tg2576 mice.

Chronic valsartan treatment is well tolerated in Tg 2576 mice. The recommended dose of valsartan for the treatment of hypertension in humans is 80–320 mg/d (24). This range corresponds to approximately 20–60 mg/kg/d in mouse, as derived using FDA criteria for converting drug equivalent dosages across species, based on body surface area ([human equivalent dose in mg/kg = animal dose in mg/kg × (animal weight in kg/human weight in kg)^0.33]; http://www.fda.gov/cber/gdlns/dose.htm). Because the overall goal of our study was to test the hypothesis that certain antihypertensive drugs may influence AD-type amyloid pathogenesis independent of blood pressure–lowering activity, we treated Tg2576 mice with either 10 or 40 mg/kg/d of valsartan, doses either approximately 2-fold below or within the recommended human equivalent dosage range (55 and 220 mg/d, respectively).

We found that chronic valsartan treatment for approximately 5 months in Tg2576 mice, delivered in the drinking water at either 10 or 40 mg/kg/d, did not significantly influence animal body weight (Figure 2A), daily fluid consumption (Figure 2B), or general metabolic status, as reflected by glucose tolerance responses (Figure 2C), assessed at approximately 11 months of age.

Figure 2

Chronic valsartan treatment is highly tolerable in Tg2576 mice. Valsartan was provided to female Tg2576 mice from 6 to 11.5 months of age at 10 mg/kg/d or 40 mg/kg/d. (A and B) Body weight and fluid consumption were monitored weekly. (C) Postprandial glucose tolerance response was examined after 5 months of valsartan treatment. (D) Tg2576 blood pressure measurements in response to approximately 5 months of valsartan treatments. (E) Baseline measurements of systolic and diastolic blood pressure and mean arterial blood pressure (MAP) in adult female Tg2576 mice and strain-, age-, sex-matched WT mice. The blood pressure determination for each animal was calculated as the mean of 10 individual measurements. Values represents group mean values ± SEM; n = 7–9 mice per group.

When we tested the potential influence of valsartan on modifications in blood pressure in Tg2576 mice, we found that valsartan delivered at either 10 or 40 mg/kg/d failed to produce a statistically significant change in either systolic, diastolic, or mean arterial blood pressure in normotensive Tg2576 mice (see below), relative to untreated age- and sex-matched Tg2576 control mice, after approximately 5 months of chronic treatment (Figure 2D). These data are consistent with a previous report that valsartan has no effect on normotensive rats (23).

In further control studies, we confirmed that adult (6–7 months old) Tg2576 mice are normotensive compared with strain-, age-, and sex-matched WT mice (Figure 2E).

Valsartan treatment attenuates AD-type cognitive deterioration coincidental with the prevention of Aβ oligomerization into soluble HMW extracellular species. The Tg2576 AD mouse model is well known to develop progressive Aβ-associated cognitive deterioration with increasing age (25). As expected, our study demonstrated that untreated control, 11-month old Tg2576 mice showed impaired acquisition of spatial learning, as assessed by the Morris water maze (MWM) test (26). The mice failed to learn to use the available visual cues to help locate a submerged escape platform, as indicated by the lack of significant improvements in the escape latency across consecutive learning trials (Figure 3A).

Figure 3

Chronic valsartan treatment of Tg2576 mice resulted in dose-dependent attenuations of AD-type spatial memory deterioration in Tg2576 mice, which is coincidental with significant reductions in HMW soluble Aβ species and AD-type neuropathology in the brains of Tg2576 mice. (A) The influence of Aβ-related spatial memory in response to valsartan treatment at 10 and 40 mg/kg/d versus the untreated control Tg2576 mice was assessed using an MWM test in approximately 11-month-old female Tg2576 mice. Latency score represents time taken to escape to the platform from the water. (B) Assessments of soluble, extracellular HMW Aβ peptide contents in the brain using an antibody specific for HMW oligomeric Aβ peptides in a dot blot analysis. Inset: Representative dot blot analysis of HMW soluble Aβ contents. (C) Assessment of total PBS-soluble Aβ peptide using ELISA assay. (D) Assessment of Aβ_1–42 and Aβ_1–40 peptide concentrations in the cerebral cortex and hippocampus of valsartan-treated (10 or 40 mg/kg/d) or control mice. (E) Stereological assessment of cerebral cortex and hippocampal Aβ plaque burden in valsartan-treated or control mice expressed as thioflavin-S–positive volume as a percentage of regional volume. Inset: Representative photograph of thioflavin-S–positive Aβ plaque neuropathology in neocortex (CTX) and hippocampal formation (H) in untreated control (left panel) and valsartan-treated (40 mg/kg/d) Tg2576 mice (right panel). Arrowheads point toward thioflavin-S positive amyloid plaques. Original magnification, ×125. Values represent group mean ± SEM; n = 7–9 mice per group. In B and C, *P < 0.001; In D and E, *P < 0.05, **P < 0.01; 1-way ANOVA followed by Newman-Keuls post-hoc analysis.

After treatment with valsartan, Tg2576 mice were able to locate the escape platform, as demonstrated by significantly reduced escape latency with progressive learning trials (Figure 3A), even when valsartan was delivered at dose equivalents approximately 2-fold lower that those commonly prescribed for the treatment of hypertension in humans (10 mg/kg/d) (F_1,7793 = 4.913, P = 0.0288 for drug treatment; F_7,23660 = 2.131, P = 0.0466 for escape latency).

Tg2576 mice treated with 40 mg/kg/d of valsartan, a dose equivalent to that commonly used for the treatment of hypertension in humans, also performed significantly better than untreated mice (F_1,19840 = 14.28_, P = 0.0003 for drug treatment; F_7,34510 = 3.549, P = 0.0018 for escape latency) (Figure 3A). The 2 valsartan-treated groups (10 mg/kg/d vs. 40 mg/kg/d) did not show significant differences in their MWM behavior test performance (P = 0.08).

In additional parallel studies using the MWM behavior test, we confirmed that the 2 doses of valsartan treatment (10 mg/kg/d and 40 mg/kg/d) not only significantly promoted the learning acquisition during the hidden-platform learning trial but also significantly promoted spatial memory retention during the probe trial (Supplemental Figure 2, A and B; supplemental material available online with this article; doi:10.1172/JC31547DS1). The valsartan treatment did not affect the visible platform learning curve, which was used in our study as control for the nonspatial factors (e.g., sensory-motor performance, motivation, etc., on MWM performance); nor did the valsartan treatment affect the swimming ability of the Tg2576 mice, as reflected by their similar swimming speed (Supplemental Figure 2, C and D).

Treatment of strain-, age-, and sex-matched WT mice with 10 or 40 mg/kg/d valsartan for approximately 5 months failed to influence spatial reference memory performance on the MWM test, compared with untreated control WT mice (Supplemental Figure 1). This finding supports the hypothesis that valsartan may benefit spatial memory reference deficits in Tg2576 mice selectively, through the attenuation of AD-type Aβ-mediated response in the brain.

Given the central role of soluble HMW extracellular Aβ oligomers in AD-type cognitive deterioration, we examined the accumulation of HMW Aβ peptides in the brain. We found that treatment of Tg 2576 mice with valsartan, at either 10 or 40 mg/kg/d, resulted in an approximately 2- to 3-fold reduction in HMW Aβ oligomers in the cerebral cortex (Figure 3B), approximately 5 months after treatment. This reduction in soluble HMW Aβ oligomers in both 10 and 40 mg/kg/d valsartan–treated animals coincided with improvement in spatial memory function in these animals. Besides the reduction in HMW oligomeric Aβ, we also found a significant reduction in total soluble Aβ peptide in the valsartan-treated mouse brains (Figure 3C).

While it is possible that the observed reduction in soluble, extracellular HMW Aβ oligomeric peptide content might be a reflection of an overall reduction in total Aβ peptide (see below; Figure 3D), we note that the ratio of soluble HMW Aβ to total soluble Aβ content in the brain of valsartan-treated Tg2576 was approximately 2-fold lower than that in the untreated Tg2576 animals, tentatively suggesting that a significant proportion of the total soluble Aβ peptides in the brain of the valsartan-treated groups is not in the neurotoxic soluble, extracellular HMW form. This evidence supports the potential role of valsartan as an inhibitor of Aβ oligomerization.

Valsartan prevents AD-type amyloid neuropathology. Treatment of Tg2576 mice with 40 mg/kg/d valsartan resulted in a 1- to 2-fold reduction in total guanidine-extractable Aβ_1–42 peptide (P < 0.05) and Aβ_1–40 peptide (P < 0.05) in the cerebral cortex and hippocampal formation (P < 0.05 and P < 0.01 for Aβ_1–42 and Aβ_1–40, respectively) (Figure 3D). We found that treatment with 10 mg/kg/d valsartan also reduced total Aβ_1–40 peptide accumulation in the brain compared with the untreated control animals (P < 0.05 for both cerebral cortex and hippocampal formation) (Figure 3D).

Finally, consistent with this evidence that valsartan treatment prevents the accumulation of total Aβ peptides in the brain, we also found a significant reduction in AD-type amyloid plaque burden in the contralateral hemisphere of the same Tg2576 mice treated with valsartan at 10 mg/kg/d (P < 0.01 for cortex; P < 0.05 for hippocampus) or 40 mg/kg/d (P < 0.01 for cortex; P < 0.05 for hippocampus), relative to age- and sex-matched untreated control Tg2576 mice, as assessed stereologically (Figure 3E).

Valsartan may beneficially influence AD pathogenesis through degradation and clearance of Aβ from the brain. To understand the mechanisms underlying the benefits of valsartan on AD-type cognitive function and Aβ neuropathology, we first examined whether valsartan can influence the processing of the APP. We found that valsartan treatment had no effect on APP holoprotein levels (C8 antibody that detects the full-length APP protein) in brain homogenates (cerebral cortex) (Figure 4A). Nor did α-, β-, and γ-secretase activities in the cerebral cortex of valsartan-treated Tg2576 mice differ from those of age- and sex-matched untreated control Tg2576 mice (Figure 4B). In addition, we found no detectable change in the content of α–, β–, or γ–carboxyterminal fragments (α-, β-, or γ-CTFs), in the brain of Tg 2576 mice treated with 10 mg/kg/d or 40 mg/kg/d relative to untreated control Tg2576 mice (P = 0.46, P = 0.25, and P = 0.23 for α-, β-, and γ-CTFs, respectively; 1-way ANOVA); similarly, no detectable changes were found in the content of soluble APPα (sAPPα) (P = 0.45) or sAPPβ (P = 0.94) in the brain of valsartan-treated mice at either 10 or 40 mg/kg/d relative to untreated control Tg2576 mice.

Figure 4

Valsartan treatments prevented cognitive impairment and attenuate AD-type neuropathology, in part, by promoting membrane-bound insulin degradation enzyme activity. (A) APP content in the cortex of valsartan-treated or untreated control Tg2576 mice. Inset: Representative immunoreactive APP (C8 antibody) and β-actin signals. (B) Assessments of cellular α-, β-, and γ-secretase activities in the cerebral cortex of Tg2576 mice in response to valsartan treatment. (C) Assessment of Aβ_1–42 and Aβ_1–40 peptide content in peripheral blood (serum). (D) Assessments of CM-associated (left panel) and cytosolic (right panel) IDE activity in the cerebral cortex of Tg2576 mice in response to valsartan treatment. Inset: Representative immunoblot signals of membrane and cytosolic IDE protein content from the same samples. (E) Assessments of neprilysin content by Western blotting using a commercial rabbit anti-mouse neprilysin antibody. Inset: Representative neprilysin and actin protein signals from the same blot. (F) Assessment of ECE activity using an Endothelin-1 ELISA System. Values represent group mean ± SEM; n = 7–9 mice per group. *P < 0.05; 1-way ANOVA, followed by Newman-Keuls post-hoc analysis.

Collectively, this evidence tentatively excludes the possibility that valsartan treatment in Tg2576 mice may prevent AD-type cognitive deterioration and AD-type neuropathology by reducing the generation of Aβ peptides in the brain from APP processing, as we also found in vitro. We note that in in vitro studies using primary Tg2576 neuron cultures, valsartan treatment had no influence on intracellular Aβ content, as assessed by Western blot analysis (data not shown).

Based on the valsartan-induced decrease in total Aβ_1–40 or Aβ_1–42 content in the brain, independent of mechanisms involving APP processing, we considered the possibility that valsartan treatment could lead to reduced levels of Aβ peptides in the serum, thereby creating a “sink effect” that promotes efflux of Aβ from the brain into the circulation (27). There was a 20%–25% dose-dependent reduction in Aβ_1–42 and Aβ_1–40 in the serum of valsartan-treated Tg2576 mice, relative to untreated controls (Figure 4C), but these changes did not reach statistical significance. It is still possible that valsartan treatment reduces the accumulation of Aβ peptides, including soluble extracellular HMW Aβ oligomers, in the brain, in part by promoting peripheral Aβ clearance.

While valsartan showed no influence on secretase activity or APP processing, we did find that valsartan treatment at 40 mg/kg/d led to a significant elevation in the activity of cell membrane–bound (CM-bound) insulin-degrading enzyme (IDE) in the cerebral cortex (P = 0.0211) (Figure 4D), accompanied by elevation of IDE protein content (Figure 4D, inset), relative to age- and sex-matched untreated control Tg2576 mice. This elevation of IDE in Tg2576 mice was highly selective, as we found no detectable changes in intracellular soluble IDE (Figure 4D), neprilysin (Figure 4E), or endothelin-converting enzyme–1 (ECE-1) (Figure 4F) in the brains of valsartan-treated Tg2576 mice, relative to age- and sex-matched Tg2576 untreated control mice.

The upregulation of IDE activity in vivo is consistent with our in vitro finding in cortico-hippocampal primary neuron cultures derived from Tg2576 embryos. We found that cotreatment of cultures with the IDE inhibitor 1,10-phenanthroline prevented valsartan-mediated Aβ_1–42–lowering activities in the conditioned medium 16 hours after treatment; Aβ_1–42 content in the conditioned medium as percentage of control cultures: vehicle-treated cultures, 100% ± 2.45%; valsartan-treated (50 μM) neuron cultures, 49.2% ± 4.7% (P < 0.001 vs. control); valsartan plus 1,10-phenanthroline–treated (60 μM) cultures, 96.0% ± 2.24% (P < 0.001 vs. valsartan alone; 1-way ANOVA followed by Newman-Keuls post-hoc analysis). Collectively, this evidence supports the central role of IDE in modulating Aβ-lowering activities in response to valsartan treatment in the brain.

Based on recent evidence showing that AD dementia is associated with reduced membrane IDE activity and content, but not soluble IDE (28), our observation suggests that valsartan treatment might reduce total Aβ content, including HMW soluble Aβ in the brain, in part, by facilitating membrane-associated IDE-mediated proteolytic cleavage of Aβ peptides.

This study was designed primarily in response to a series of epidemiological and clinical studies reporting mixed results on the association of the use of antihypertensive drugs and AD incidence (1–5). To clarify whether any of the currently available antihypertensive medications could provide beneficial AD-modifying activity, we surveyed 55 antihypertensive drugs for their potential beneficial role in AD-type amyloid neuropathology. Seven of these were identified to significantly reduce Aβ accumulation in vitro. Among these 7 drugs tested for antioligomerization activity, we found valsartan, and to a lesser extent losartan, to be the only drugs capable of attenuating oligomerization of Aβ peptides into soluble HMW oligomeric Aβ species in vitro.

Valsartan treatment prevents Aβ-related spatial memory reference deficits and AD-type neuropathology in vivo at doses equivalent to or lower than the recommended dose for humans. In our study we found that treatment of Tg2576 mice with valsartan at a concentration as low as 10 mg/kg/d attenuated spatial reference memory deterioration that coincided with an approximately 3-fold reduction in HMW Aβ peptide content in the brain, while IDE activity and the content of total Aβ_1–42 (but not total Aβ_1–40) were unaffected. We hypothesize that treatment with the low valsartan dose most likely beneficially influences AD-type spatial memory deterioration through direct interaction of valsartan with Aβ peptides in the brain (as we found in vitro) and prevents the generation of soluble, extracellular HMW Aβ species. This activity is independent of IDE promotion. This scenario is consistent with the recent study showing that extracellular, soluble HMW oligomeric Aβ peptides purified from the brain of middle-aged, impaired Tg2576 mice could disrupt memory functions, even episodically, when administered to normal rats (18). In addition to preventing Aβ oligomerization, we found that the higher dose of valsartan (40 mg/kg/d) also significantly promoted CM-IDE activity in the cerebral cortex of Tg2576 mice. This increase in CM-IDE activity was highly selective, as there was no detectable change in other proteases involved in the clearance of Aβ (e.g., neprilysin and ECE). Thus at the higher dose, valsartan most likely benefited spatial memory functions in Tg2576 mice by simultaneously increasing Aβ degradation by IDE and reducing Aβ aggregation into soluble, extracellular HMW Aβ species.

Finally, an additional mechanism through which valsartan prevents Aβ-related spatial memory impairment and AD-type neuropathology may be through the promotion of Aβ “sinking” from the brain to the periphery, as suggested by the decreased level of serum Aβ in valsartan-treated Tg2576 mice. However, our results did not reach statistical significance. Additional studies will clarify whether valsartan treatment may also reduce Aβ neuropathology by promoting Aβ sinking from the brain to the periphery.

Collectively, our evidence suggests that valsartan treatment might prevent Aβ-related spatial memory reference deficits in the Tg2576 AD mouse model through a combination of multiple mechanisms: (a) reducing Aβ aggregation into HMW Aβ species; (b) increasing Aβ degradation by IDE; and possibly (c) promoting sinking of Aβ peptides from the brain to the periphery.

Valsartan beneficially prevented Aβ-related spatial memory reference deficit in Tg2576 mice at a dose less than the equivalent recommended clinical dose for hypertensive treatment. While there are as yet no data in humans to support the idea that angiotensin receptor–blocking drug valsartan has any impact on the incidence or progression of cognitive impairment, this study may provide the appropriate impetus for clinical trials in vulnerable human subjects, such as patients with mild cognitive impairment, at subclinical doses.

Aside from valsartan, we identified 6 antihypertensive drugs that significantly reduced accumulations of Aβ peptides in vitro in primary Tg2576 cortico-hippocampal neuron cultures. While our evidence supports the in vivo efficacy of valsartan to attenuate AD-type phenotypes in Tg2576 AD mouse model, we have not yet determined the in vivo efficacy of the other 6 Aβ-lowering antihypertensive drugs. Many factors, including biological availability and drug metabolism, may influence Aβ-lowering activity of a drug in vivo. It would not be surprising if some drugs that are biologically active in vitro were not effective in vivo. Thus, individual drugs must be investigated on a case-by-case basis. Ongoing studies in our laboratory are evaluating the remaining 6 antihypertensives individually for their in vivo efficacy to protect against progressive Aβ neuropathology and Aβ-related memory deficits in AD.

View Supplemental data

View Sidebar

This work was supported by the Altschul Foundation; the James J. Peters VA Geriatrics, Research, Education and Clinical Center Program; and National Institute on Aging grant AG02219 to G.M. Pasinetti.

Address correspondence to: Giulio Maria Pasinetti, Icahn Research Institute, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1230, New York, New York 10029, USA. Phone: (212) 659-8716 or (212) 659-8740; Fax: (212) 876-9042; E-mail: giulio.pasinetti@mssm.edu.

Nonstandard abbreviations used: Aβ, β-amyloid protein; AD, Alzheimer disease; APP, amyloid precursor protein; ARB, angiotensin II type 1 receptor blocker; CM, cell membrane; CTF, carboxyterminal fragment; ECE-1, endothelin-converting enzyme–1; HMW, high-molecular-weight; IDE, insulin-degrading enzyme; MWM, Morris water maze; sAPP, soluble APP.

Conflict of interest: The authors have declared that no conflict of interest exists.

Reference information: J. Clin. Invest.117:3393–3402 (2007). doi:10.1172/JCI31547

1. Lopez-Arrieta, J.M., Birks, J. 2002. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 3:CD000147.
   View this article via: PubMed Google Scholar
2. Khachaturian, A.S., et al. 2006. Antihypertensive medication use and incident Alzheimer disease: the Cache County study. Arch. Neurol. 63:686-692.
   View this article via: CrossRef PubMed Google Scholar
3. Guo, Z.C., Viitanen, M., Winblad, B., Fratiglioni, L. 1999. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. J. Am. Geriatr. Soc. 47:723-726.
   View this article via: PubMed Google Scholar
4. Forette, F., et al. 2002. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162:2046-2052.
   View this article via: CrossRef PubMed Google Scholar
5. in’t Veld, B.A., Ruitenberg, A., Hofman, A., Stricker, B.H., Breteler, M.M. 2000. Antihypertensive drugs and incidence of dementia: the Rotterdam study. Neurobiol. Aging. 54:A397.
6. Singer, R.B. 1991. Stroke in the elderly treated for systolic hypertension (SHEP). J. Insur. Med. 23:265-269.
   View this article via: PubMed Google Scholar
7. Prince, M.J., Bird, A.S., Blizard, R.A., Mann, A.H. 1996. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s treatment trial of hypertension in older adults. BMJ. 312:801-805.
   View this article via: PubMed Google Scholar
8. Lithell, H., et al. 2004. The Study on Cognition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 22:1605-1612.
   View this article via: CrossRef PubMed Google Scholar
9. Selkoe, D.J. 2001. Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81:741-766.
   View this article via: PubMed Google Scholar
10. Busciglio, J., Gabuzda, D.H., Matsudaira, P., Yankner, B.A. 1993. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. U. S. A. 90:2092-2096.
    View this article via: CrossRef PubMed Google Scholar
11. Haass, C., et al. 1992. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 359:322-325.
    View this article via: CrossRef PubMed Google Scholar
12. Shoji, M., et al. 1992. Production of the Alzheimer amyloid-beta protein by normal proteolytic processing. Science. 258:126-129.
    View this article via: CrossRef PubMed Google Scholar
13. Esch, F.S., et al. 1990. Cleavage of amyloid-beta peptide during constitutive processing of its precursor. Science. 248:1122-1124.
    View this article via: CrossRef PubMed Google Scholar
14. Walsh, D.M., et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535-539.
    View this article via: CrossRef PubMed Google Scholar
15. Lesne, S., et al. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 440:352-357.
    View this article via: CrossRef PubMed Google Scholar
16. Kotilinek, L.A., et al. 2002. Reversible memory loss in a mouse transgenic model of Alzheimer’s disease. J. Neurosci. 22:6331-6335.
    View this article via: PubMed Google Scholar
17. Jacobsen, J.S., et al. 2006. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A. 103:5161-5166.
    View this article via: CrossRef PubMed Google Scholar
18. Cleary, J.P., et al. 2005. Natural oligomers of the amyloid-[beta] protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84.
    View this article via: CrossRef PubMed Google Scholar
19. Klyubin, I., et al. 2005. Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11:556-561.
    View this article via: CrossRef PubMed Google Scholar
20. Mirjany, M., Ho, L., Pasinetti, G.M. 2002. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J. Pharmacol. Exp. Ther. 301:494-500.
    View this article via: PubMed Google Scholar
21. Klein, W.L. 2002. Abeta toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41:345-352.
    View this article via: CrossRef PubMed Google Scholar
22. McLaurin, J., et al. 2002. Therapeutically effective antibodies against amyloid-[beta] peptide target amyloid-[beta] residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 8:1263-1269.
    View this article via: CrossRef PubMed Google Scholar
23. Yamamoto, S., et al. 1997. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist — 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneimittelforschung. 47:604-612.
    View this article via: PubMed Google Scholar
24. PDR.net. http://www.pdr.net.
25. Hsiao, K., et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
    View this article via: CrossRef PubMed Google Scholar
26. Morris, R. 1984. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 11:47-60.
    View this article via: CrossRef PubMed Google Scholar
27. Morgan, D. 2005. Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener. Dis. 2:261-266.
    View this article via: CrossRef PubMed Google Scholar
28. Zhao, Z., et al. 2007. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer’s disease. Neurobiol. Aging. 28:824-830.
    View this article via: CrossRef PubMed Google Scholar
29. Wang, J., et al. 2005. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. Faseb J. 19:659-661.
    View this article via: PubMed Google Scholar
30. Kawarabayashi, T., et al. 2001. Age-dependent changes in brain, CSF, and plasma amyloid {beta} protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J. Neurosci. 21:372-381.
    View this article via: PubMed Google Scholar
31. Takeda, K., et al. 2003. Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency. J. Endocrinol. 176:237-246.
    View this article via: CrossRef PubMed Google Scholar
32. McLaurin, J., et al. 2006. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med. 12:801-808.
    View this article via: CrossRef PubMed Google Scholar
33. Vallet, P.G., et al. 1992. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer’s disease. Acta Neuropathologica. 83:170-178.
    View this article via: CrossRef PubMed Google Scholar
34. Ho, L., et al. 2004. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 18:902-904.
    View this article via: PubMed Google Scholar
35. Qiu, W.Q., et al. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273:32730-32738.
    View this article via: CrossRef PubMed Google Scholar
36. Zhao, Z., et al. 2005. Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer’s disease beta-amyloid neuropathology. FASEB J. 19:2081-2082.
    View this article via: PubMed Google Scholar
37. Lopez-Ongil, S., et al. 2005. Crosstalk between mesangial and endothelial cells: angiotensin II down-regulates endothelin-converting enzyme 1. Cell. Physiol. Biochem. 15:135-144.
    View this article via: CrossRef PubMed Google Scholar
38. Takahashi, M., et al. 1995. Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem. J. 311:657-665.
    View this article via: PubMed Google Scholar
39. Martindale. 2007. The complete drug reference. The Pharmaceutical Press. http://www.medicinescomplete.com/mc/martindale/current/contents.htm.